Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis

Abstract Introduction Ritlecitinib, an oral, selective dual inhibitor of Janus kinase (JAK) 3 and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, is approved for treating severe alopecia areata (AA) in patients aged ≥ 12 years in the USA. This study describes characterist...

Descripció completa

Dades bibliogràfiques

Autors principals:	Samantha K. Kurosky, Ashley S. Cha-Silva, Jenny Austin, Arash Mostaghimi, Chesahna Kindred, Genevieve Gauthier, Mojgan Sadrarhami, Peter Anderson, Benjamin Ungar
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2026-05-01
Col·lecció:	Dermatology and Therapy
Matèries:	Alopecia areata Real-world data Ritlecitinib
Accés en línia:	https://doi.org/10.1007/s13555-026-01773-3
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!